A5073237061- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Prostate Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Immunotherapy and Immune Responses
- Urological Disorders and Treatments
- Chemokine receptors and signaling
- Immune cells in cancer
- Metastasis and carcinoma case studies
- Inflammatory Biomarkers in Disease Prognosis
- Bone health and treatments
- Ovarian cancer diagnosis and treatment
- Radiopharmaceutical Chemistry and Applications
- Photodynamic Therapy Research Studies
- Urologic and reproductive health conditions
- RNA Research and Splicing
- Immune Cell Function and Interaction
- Peptidase Inhibition and Analysis
- Radiomics and Machine Learning in Medical Imaging
- Nanoplatforms for cancer theranostics
Kanazawa University
2022-2025
Enfortumab vedotin (EV) is an established pharmacotherapy for metastatic urothelial carcinoma (mUC); however, its adverse events (AEs) cannot be overlooked. The study investigated the efficacy and safety of biweekly EV administration.
Intraoperative hypotension remains a serious adverse event of photodynamic diagnosis-assisted transurethral resection bladder tumor with oral administration 5-aminolevulinic acid. We conducted re-analysis perioperative in the acid to ascertain its safety.
Abstract Objective Prostate-specific antigen is considered the most useful biomarker for prostate cancer, but not in all cases. In a previous study, we have shown that risk classification combining prostate-specific ≥100 ng/mL and chemokine (CC motif) ligand 2 ≥ 320 pg/mL can predict survivals. We investigated long-term usefulness of serum as complementary to developed novel system. Methods Serum samples were collected from 379 patients who underwent biopsy at Kanazawa University Hospital...
The suppression of androgen receptor (AR) expression exacerbates the migration potential prostate cancer. This study identified a previously unrecognized regulation AR-controlled pathway that promotes in cancer cells. Prostate cells pass through transwell membrane (mig cells) have higher with decreased AR than parental In this study, we aimed to elucidate mechanism enhancement associated signaling. Expression C-C motif ligand 20 (CCL20) is upregulated mig cells, unlike Knockdown small...
Bone is a common site of prostate cancer metastasis. turnover markers n-terminal propeptide type I procollagen (P1NP) and tartrate-resistant acid phosphatase 5b (TRACP-5b) are highly sensitive to bone remodeling activity. However, their prognostic significance as unknown. This study retrospectively examined the usefulness P1NP TRACP-5b biomarkers. Castration-resistant recurrence-free survival (CFS) was estimated using Kaplan–Meier method. A predictive model for CFS constructed multivariate...
Purpose: Prostate-specific antigen (PSA) is a useful prostate cancer (PC) biomarker, but some cases reported that PSA does not correlate with the Gleason score. Serum chemokine (CC motif) ligand 2 (CCL2) has been to be potential complementary it remains unclear whether can applied non-metastatic castration-sensitive (nmCSPC) or each section of stages. CCL2′s usefulness was investigated as prognostic nmCSPC biomarker in this study. Methods: samples were collected from 379 patients who...
The percentage of positive cores (PPC) is increasingly recognized as a prognostic factor in prostate cancer. However, the usefulness PPC for patients undergoing androgen deprivation therapy (ADT) and high-risk group has not been adequately studied.A retrospective analysis was conducted 255 who underwent biopsy (all-case group). We examined efficacy biomarker.Eighty-nine were treated with ADT alone (ADT group), 107 classified (high-risk median duration follow-up 112.4 months, 85.3 110.0...
Introduction Low‐dose‐rate brachytherapy is performed for localized prostate cancer. We report the first case of a bladder stone encompassing seed migrated into in patient treated with low‐dose‐rate brachytherapy. Case presentation A man was diagnosed cancer and underwent After 2 months, dysuria occurred, ultrasonography revealed needle‐shaped high‐intensity protruding from bladder. Cystoscopy examination found link connector. With possibility natural dissolution link, careful observation...
Purpose To compare the prognosis and quality of life between radical cystectomy bladder conservative treatment for muscle invasive cancer in real world. Materials Methods Patients treated without metastases were retrospectively evaluated overall survival, progression‐free rehospitalization. Results Of 141 patients, 62 underwent 79 cystectomy. who had significantly better survival (HR: 1.83, 95% CI: 1.12–3.00; p < 0.01) 1.82, 0.99–3.34; = 0.03) than those treatment. However, there was no...
Abstract We focused on Tumor-Associated Macrophages (TAM) and explored its effects bladder cancer (BC). Co-culturing PMA-treated THP-1 with BC cell lines (UMUC3 T24) induced to develop suppressed CD68 increased CD206 expression which differentiated into M2-like macrophages. Co-culture of TAM this macrophage enhanced the migration invasive activities BC, as well EMT marker. Human cytokine antibody array conditioned medium from co-culture showed high CCL20, CCL2 CXCL7. qPCR revealed that these...
Abstract Background: The percentage of positive cores (PPC) is increasingly recognized as a prognostic factor in prostate cancer. However, the usefulness PPC for patients undergoing androgen deprivation therapy (ADT) and high-risk group has not been adequately studied. Methods: A retrospective analysis was conducted 255 who underwent biopsy (all-case group). We examined efficacy biomarker. Results: Eighty-nine were treated with ADT alone (ADT group), 107 classified (high-risk median duration...
Despite treating advanced prostate cancer (PCa) with androgen deprivation therapy, it eventually progresses to castration-resistant PCa. Subsequently, taxanes are administered, but when PCa becomes resistant taxanes, another treatment is needed, which has not yet been established. We previously synthesized a novel α-trifluoromethyl chalcone, YS71, and reported its antitumor effects against cells. In this study, we confirmed efficacy androgen-sensitive, androgen-independent, taxane-resistant...